Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders [1]

British Journal of Dermatology

Volumn 147, Issue 2, 2002, Pages 385-

  Beretta, L ^a   Caronni, M ^a   Vanoli, M ^a   Scorza, Raffaela ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; HLA ANTIGEN CLASS 1; HYDROXYUREA; ILOPROST; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CASE REPORT; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAPLOTYPE; HEART FUNCTION; HUMAN; IMMUNOLOGICAL TOLERANCE; KARYOTYPING; KIDNEY FUNCTION; LABORATORY TEST; LETTER; LUNG FUNCTION TEST; METAPHASE; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

EID: 0036378075     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.48901.x     Document Type: Letter

References (13)

1. Jonasch E, Haluska FG. Interferon in oncological practice. Review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55.
2. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Int Med 1991; 115: 178-83.
3. Conlon KC, Urba WJ, Smith JW et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990; 65: 2237-42.
4. Wandl UB, Nagel-Hiemke M, May D et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70-4.
5. Cavanna L, Vallisa D, Berte R et al. Severe immune thrombocytopenic purpura relapse after alpha-interferon in chronic myeloid leukemia, successfully treated with cyclosporine. Am J Hematol 1994; 47: 255-6.
6. Akard LP, Hoffman R, Elias L et al. Alpha-interferon and immune hemolytic anemia. Ann Int Med 1986; 105: 306 (Letter).
7. Guerci AP, Guerci P, Levy-Marchal C. Onset of insulin-dependent diabetes mellitus after interferon-alpha therapy for hairy cell leukaemia. Lancet 1994; 343: 1167-8.
8. Bora I, Karli N, Bakar M et al. Myasthenia gravis following IFN-alpha-2a treatment. Eur Neurol 1997; 38: 68.
9. Fattovich G, Giustina G, Favarato S et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. The Italian Association for the Study of the Liver. J Hepatol 1996; 24: 38-47.
10. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
11. Black CM, Silman AJ, Herrick AI et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma. Arthritis Rheum 1999; 42: 299-305.
12. Scorza R, Coppola C, Molteni M et al. HLA-DR antigens, clinical manifestations and autoantibodies in systemic sclerosis (scleroderma). J Immunol Immunopharmacol 1992; 12: 157-62.
13. Clements P, Lachenbruch P, Seibold JR et al. Inter- and intraob-server variability of total skin score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.